Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells $121,486.47 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,799 shares of the company’s stock in a transaction on Friday, May 16th. The stock was sold at an average price of $67.53, for a total transaction of $121,486.47. Following the sale, the insider now directly owns 84,797 shares in the company, valued at $5,726,341.41. This trade represents a 2.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, May 15th, Martina M.D. Flammer sold 9,925 shares of Insmed stock. The shares were sold at an average price of $65.47, for a total transaction of $649,789.75.
• On Wednesday, May 14th, Martina M.D. Flammer sold 1,744 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total transaction of $114,423.84.
• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total value of $570,146.48.

Insmed Price Performance

Shares of Insmed stock opened at $66.02 on Thursday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $12.02 billion, a price-to-earnings ratio of -11.81 and a beta of 0.84. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a 50-day simple moving average of $71.11 and a two-hundred day simple moving average of $73.08.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.06) earnings per share. Analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Institutional Trading of Insmed

Several large investors have recently modified their holdings of INSM. Jennison Associates LLC raised its position in shares of Insmed by 0.6% in the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after buying an additional 4,560 shares in the last quarter. abrdn plc boosted its holdings in shares of Insmed by 159.5% in the 4th quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company’s stock valued at $19,998,000 after purchasing an additional 178,041 shares in the last quarter. Moody Aldrich Partners LLC bought a new position in shares of Insmed in the 4th quarter valued at $2,449,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Insmed by 14.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 37,934 shares of the biopharmaceutical company’s stock worth $2,619,000 after buying an additional 4,882 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Insmed by 8.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 423,094 shares of the biopharmaceutical company’s stock worth $29,590,000 after buying an additional 32,960 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have issued reports on INSM. Stifel Nicolaus dropped their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Monday, May 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Finally, Bank of America raised their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.